Related Experiment Videos
Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies
1Departments of Surgery and Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Surgical Oncology Clinics of North America
|September 12, 1998
Summary
Adrenocortical cancers are rare endocrine tumors with poor survival rates. Surgical removal is the only proven survival-prolonging therapy, while mitotane chemotherapy offers benefits for a subset of patients.
Area of Science:
- Endocrinology
- Oncology
Background:
- Adrenocortical cancers are rare endocrine malignancies.
- Tumors often present at advanced stages with metastasis, leading to a poor 5-year survival rate of 20% to 35%.
Purpose of the Study:
- To review the current therapeutic landscape for adrenocortical cancers.
- To highlight the role of surgery and chemotherapy in managing these rare tumors.
Main Methods:
- Review of existing literature on adrenocortical cancer treatment.
- Analysis of survival data related to different therapeutic interventions.
Main Results:
- Surgical resection is the only established method for prolonging survival in adrenocortical cancer.
- Mitotane is the standard chemotherapy, with approximately 20% to 25% of patients experiencing prolonged survival upon response.
Conclusions:
- Adrenocortical cancer management relies heavily on surgical intervention.
- Mitotane chemotherapy provides a survival benefit for a specific patient group, underscoring the need for further research into more effective treatments.